

DAFTAR PUSTAKA

- Al-dahhan, N.A.A., Albairi, A.J. and Hamad, A.J. (2021) 'Assessment of Neutrophil-to-Lymphocyte Ratio, Platelet-to Lymphocyte Ratio, Oxidative Stress and Anti Oxidants levels in Polycystic Ovary Syndrome Patients with Low-Grade Chronic Inflammation', *Medico-Legal Update*, 21(1), pp. 644–652. Available at: <https://doi.org/10.37506/mlu.v21i1.2386>.
- Amer, H., Kartikasari, A.E.R. and Plebanski, M. (2021) 'Elevated interleukin-6 levels in the circulation and peritoneal fluid of patients with ovarian cancer as a potential diagnostic biomarker: A systematic review and meta-analysis', *Journal of Personalized Medicine*, 11(1335). Available at: <https://doi.org/10.3390/jpm11121335>.
- Atallah, G., Abd Aziz, N. and Kampan, N. (2021) 'New Predictive Biomarkers for Ovarian Cancer', *Diagnostics (Basel)*, 11(3), p. 465. Available at: <https://doi.org/doi:10.3390/diagnostics11030465>.
- Babaier, A. and Ghatage, P. (2020) 'Mucinous cancer of the ovary: Overview and current status', *Diagnostics*, 10(1), pp. 1–16. Available at: <https://doi.org/10.3390/diagnostics10010052>.
- Badora-Rybicka, A., Nowara, E. and Starzyczny-Słota, D. (2016) 'Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer', *ESMO Open*, 1(2), pp. 1–5. Available at: <https://doi.org/10.1136/esmoopen-2016-000039>.
- Baert, T., Ferrero, A., Sehouli, J., O'Donnell, D.M., González-Martín, A., Joly, F., van der Velden, J., Blecharz, P., Tan, D.S.P., Querleu, D., Colombo, N., du Bois, A. and Ledermann, J.A. (2021) 'The systemic treatment of recurrent ovarian cancer revisited', *Annals of Oncology*, 32(6), pp. 710–725. Available at: <https://doi.org/10.1016/j.annonc.2021.02.015>.

- El Bairi, K., Al Jarroudi, O. and Afqir, S. (2021) 'Inexpensive Systemic Inflammatory Biomarkers in Ovarian Cancer: An Umbrella Systematic Review of 17 Prognostic Meta-Analyses', *Frontiers in Oncology*, 11(September). Available at: <https://doi.org/10.3389/fonc.2021.694821>.
- Bakacak, M., Serin, S., Ercan, Ö., Köstü, B., Bostancı, M., Bakacak, Z., Kıran, H. and Kıran, G. (2016) 'Utility of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to distinguish malignant from benign ovarian masses', *J Turk Ger Gynecol Assoc*, 17(1), pp. 21–25. Available at: <https://doi.org/10.5152/jtgga.2015.0152>.
- Balescu, I., Brezean, I., Cauni, V., Petrea, S., Diaconu, C., Gaspar, B., Ciuvica, A., Nistor, C.E., Ciuche, A., Varlas, V. and Bacalbasa, N. (2023) 'Platelet to Lymphocyte Ratio as a Predictive Tool for the Perioperative and Postoperative Outcomes in Advanced Stage Ovarian Cancer', *Chirurgia (Romania)*, 118(4), pp. 417–425. Available at: <https://doi.org/10.21614/chirurgia.2023.v.118.i.4.p.417>.
- Barr, C.E., Njoku, K., Owens, G.L. and Crosbie, E.J. (2023) 'Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women', *Cancers*, 15(4), pp. 1–13. Available at: <https://doi.org/10.3390/cancers15041256>.
- Bast, R.C., Han, C.Y., Lu, Z. and Lu, K.H. (2021) 'Next steps in the early detection of ovarian cancer', *Communications Medicine*, 1(36), pp. 36–38. Available at: <https://doi.org/10.1038/s43856-021-00037-9>.
- Berek, J., Crum, C. and Friedlander, M. (2015) 'FIGO Cancer Report 2015: Cancer of the ovary, fallopian tube, and peritoneum', *Elsevier*, pp. S11–S122.
- Budiana, I.N.G., Angelina, M. and Pemayun, T.G.A. (2019) 'Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery', *Journal of the Turkish-German Gynecological Association*, 20(1), pp. 47–54. Available at: <https://doi.org/10.4274/jtgga.galenos.2018.2018.0119>.

- Cardenas, C., Alvero, A.B., Yun, B.S. and Mor, G. (2016) ‘Redefining the origin and evolution of ovarian cancer: A hormonal connection’, *Endocrine-Related Cancer*, 23(9), pp. R411–R422. Available at: <https://doi.org/10.1530/ERC-16-0209>.
- Chang, L.C., Huang, C.F., Lai, M.S., Shen, L.J., Wu, F.L.L. and Cheng, W.F. (2018) ‘Prognostic factors in epithelial ovarian cancer: A population-based study’, *PLoS ONE*, 13(3), pp. 1–11. Available at: <https://doi.org/10.1371/journal.pone.0194993>.
- Charkhch, P., Cybulski, C., Gronwald, J., Wong, F.O., Narod, S.A. and Akbari, M.R. (2020) ‘CA125 and Ovarian Cancer: A Comprehensive review’, *Cancers*, 12(3730), pp. 1–29.
- Dahlan, M.S. (2016) *Besar Sampel dalam Penelitian Kedokteran dan Kesehatan*. 4th edn. Epidemiologi Indonesia.
- Dilley, J., Burnell, M., Gentry-Maharaj, A., Ryan, A., Neophytou, C., Apostolidou, S., Karpinskyj, C., Kalsi, J., Mould, T., Woolas, R., Singh, N., Widschwendter, M., Fallowfield, L., Campbell, S., Skates, S.J., McGuire, A., Parmar, M., Jacobs, I. and Menon, U. (2020) ‘Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the “no screen” arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)’, *Gynecologic Oncology*, 158, pp. 316–322. Available at: <https://doi.org/10.1016/j.ygyno.2020.05.002>.
- Dochez, V., Cailon, H., Vaucel, E., Dimet, J., Winer, N. and Ducarme, G. (2019) ‘Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review’, *J Ovarian Res*, 12(1), p. 28. Available at: <https://doi.org/doi:10.1186/s13048-019-0503-7>.
- Doubeni, C.A., Doubeni, A.R.B. and Myers, A.E.M. (2016) ‘Diagnosis and Management of Ovarian Cancer’, *American Family Physician*, 93(11), pp. 937–944.

Eo, W.K., Chang, H.J., Kwon, S.H., Koh, S.B., Kim, Y.O., Ji, Y. Il, Kim, H.B., Lee, J.Y., Suh, D.S., Kim, K.H., Chang, I.J., Kim, H.Y. and Chang, S.C. (2016) ‘The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of ovarian cancer’, *Journal of Cancer*, 7(3), pp. 289–296. Available at: <https://doi.org/10.7150/jca.13432>.

Eo, W.K., Kim, K.H., Park, E.J., Kim, H.Y., Kim, H. bae, Koh, S.B. and Namkung, J. (2018) ‘Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses’, *Journal of Cancer*, 9(7), pp. 1165–1172. Available at: <https://doi.org/10.7150/jca.23606>.

Funston, G., Mounce, L.T.A., Price, S., Rous, B., Crosbie, E.J., Hamilton, W. and Walter, F.M. (2021) ‘CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: A retrospective cohort study using electronic health records’, *British Journal of General Practice*, pp. E465–E472. Available at: <https://doi.org/10.3399/BJGP.2020.0859>.

Hardikar, N.S. (2021) ‘The Importance of Early Detection of Ovarian Cancer: Epidemiology and Risk Factors’, *Basic & Clinical Cancer Research*, 13(03), pp. 201–209.

Huang, H., Wu, K., Chen, L. and Lin, X. (2021) ‘Study on the Application of Systemic Inflammation Response Index and Platelet–Lymphocyte Ratio in Ovarian Malignant Tumors’, *International Journal of General Medicine*, 14, pp. 10015–10022. Available at: <https://doi.org/10.2147/IJGM.S346610>.

Huber, D., Seitz, S., Kast, K., Emons, G. and Ortmann, O. (2020) ‘Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review’, *Archives of Gynecology and Obstetrics*, 301(4), pp. 875–884. Available at: <https://doi.org/10.1007/s00404-020-05458-w>.

- Husby, A., Wohlfahrt, J. and Melbye, M. (2022) 'Pregnancy duration and ovarian cancer risk: A 50-year nationwide cohort study', *International Journal of Cancer*, 151(10), pp. 1717–1725. Available at: <https://doi.org/10.1002/ijc.34192>.
- Iversen, L., Fielding, S., Lidegaard, Ø., Mørch, L.S., Skovlund, C.W. and Hannaford, P.C. (2018) 'Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: Prospective, nationwide cohort study', *BMJ (Online)*, 362, pp. 1–9. Available at: <https://doi.org/10.1136/bmj.k3609>.
- Karpinskyj, C., Burnell, M., Gonzalez-Izquierdo, A., Ryan, A., Kalsi, J., Jacobs, I., Parmar, M., Menon, U. and Gentry-Maharaj, A. (2020) 'Socioeconomic status and ovarian cancer stage at diagnosis: A study nested within UKCToCs', *Diagnostics*, 10(2), pp. 1–14. Available at: <https://doi.org/10.3390/diagnostics10020089>.
- Kotsopoulos, J., Gronwald, J., McCuaig, J.M., Karlan, B.Y., Eisen, A., Tung, N., Bordeleau, L., Senter, L., Eng, C., Couch, F., Fruscio, R., Weitzel, J.N., Olopade, O., Singer, C.F., Pal, T., Foulkes, W.D., Neuhausen, S.L., Sun, P., Lubinski, J. and Narod, S.A. (2020) 'Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation', *Gynecologic Oncology*, 159, pp. 820–826. Available at: <https://doi.org/10.1016/j.ygyno.2020.09.037>.
- Kurman, R.J. and Shih, I.M. (2016) 'The dualistic model of ovarian carcinogenesis revisited, revised, and expanded', *American Journal of Pathology*, 186(4), pp. 733–747. Available at: <https://doi.org/10.1016/j.ajpath.2015.11.011>.

Kwon, B.S., Jeong, D.H., Byun, J.M., Lee, T.H., Choi, K.U., Song, Y.J., Suh, D.S. and Kim, K.H. (2018) 'Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma', *Journal of Cancer*, 9(7), pp. 1127–1134. Available at: <https://doi.org/10.7150/jca.24057>.

Kyo, S., Ishikawa, N., Nakamura, K. and Nakayama, K. (2020) 'The fallopian tube as origin of ovarian cancer: Change of diagnostic and preventive strategies', *Cancer Medicine*, 9(2), pp. 421–431. Available at: <https://doi.org/10.1002/cam4.2725>.

Landolfo, C., Achten, E.T.L., Ceusters, J., Baert, T., Froyman, W., Heremans, R., Vanderstichele, A., Thirion, G., Van Hoylandt, A., Claes, S., Oosterlynck, J., Van Rompuy, A.S., Schols, D., Billen, J., Van Calster, B., Bourne, T., Van Gorp, T., Vergote, I., Timmerman, D. and Coosemans, A. (2020) 'Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors', *Gynecologic Oncology*, 159(3), pp. 811–819. Available at: <https://doi.org/10.1016/j.ygyno.2020.09.025>.

Lawson-Michod, K.A., Watt, M.H., Grieshober, L., Green, S.E., Karabegovic, L., Derzon, S., Owens, M., McCarty, R.D., Doherty, J.A. and Barnard, M.E. (2022) 'Pathways to ovarian cancer diagnosis: a qualitative study', *BMC Women's Health*, 22(430), pp. 1–16. Available at: <https://doi.org/10.1186/s12905-022-02016-1>.

- Leblanc, E., Narducci, F., Ferron, G., Mailliez, A., Charvolin, J.Y., Houssein, E.H., Guyon, F., Fourchette, V., Lambaudie, E., Crouzet, A., Fouche, Y., Gouy, S., Collinet, P., Caquant, F., Pomel, C., Golfier, F., Vaini-Cowen, V., Fournier, I., Salzert, M., Tresch, E., Probst, A., Lemaire, A.S., Deley, M.C. Le and Hudry, D. (2023) 'Prophylactic Radical Fimbriectomy with Delayed Oophorectomy in Women with a High Risk of Developing an Ovarian Carcinoma: Results of a Prospective National Pilot Study', *Cancers*, 15(1141), pp. 1–15. Available at: <https://doi.org/10.3390/cancers15041141>.
- Leong, E., Ong, S.K., Jali, F. and Naing, L. (2022) 'Incidence, Mortality and Survival Analysis of Epithelial Ovarian Cancer in Brunei Darussalam', *Asian Pacific Journal of Cancer Prevention*, 23(4), pp. 1415–1423. Available at: <https://doi.org/10.31557/APJCP.2022.23.4.1415>.
- Li, L., Tian, J., Zhang, L., Liu, L., Sheng, C., Huang, Y., Zheng, H., Song, F. and Chen, K. (2021) 'Utility of preoperative inflammatory markers to distinguish epithelial ovarian cancer from benign ovarian masses', *Journal of Cancer*, 12(9), pp. 2687–2693. Available at: <https://doi.org/10.7150/JCA.51642>.
- Main, C., Chen, X., Chamley, L.W., Zhao, M. and Chen, Q. (2022) 'Understanding How Pregnancy Protects Against Ovarian and Endometrial Cancer Development: Fetal Antigens May Be Involved', *Endocrinology (United States)*, 163, pp. 1–6. Available at: <https://doi.org/10.1210/endocr/bqac141>.
- Mallen, A., Todd, S., Robertson, S.E., Kim, J., Sehovic, M., Wenham, R.M., Extermann, M. and Chon, H.S. (2021) 'Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer', *Gynecologic Oncology*, 161(3), pp. 693–699. Available at: <https://doi.org/10.1016/j.ygyno.2021.03.008>.

- Mancari, R., Cutillo, G., Bruno, V., Vincenzoni, C., Mancini, E., Baiocco, E., Bruni, S., Vocaturo, G., Chiofalo, B. and Vizza, E. (2020) ‘Development of new medical treatment for epithelial ovarian cancer recurrence’, *Gland Surgery*, 9(4), pp. 1149–1163. Available at: <https://doi.org/10.21037/gs-20-413>.
- Matsas, A., Stefanoudakis, D., Troupis, T., Kontzoglou, K., Eleftheriades, M., Christopoulos, P., Panoskaltis, T., Stamoula, E. and Iliopoulos, D.C. (2023) ‘Tumor Markers and Their Diagnostic Significance in Ovarian Cancer’, *Life*, 13(8), pp. 1–18. Available at: <https://doi.org/10.3390/life13081689>.
- Mogensen, J.B., Kjær, S.K., Mellekjær, L. and Jensen, A. (2016) ‘Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study’, *Gynecologic Oncology*, 143(1), pp. 87–92. Available at: <https://doi.org/10.1016/j.ygyno.2016.07.095>.
- Momenimovahed, Z., Taheri, S., Tiznobaik, A. and Salehiniya, H. (2022) ‘Is Pregnancy Characteristic Associated with Ovarian Cancer? A Review of the Available Evidence’, *Eurasian Journal of Medicine and Oncology*, 6(3), pp. 198–209. Available at: <https://doi.org/10.14744/ejmo.2021.14462>.
- Momenimovahed, Z., Tiznobaik, A., Taheri, S. and Salehiniya, H. (2019) ‘Ovarian cancer in the world: Epidemiology and risk factors’, *International Journal of Women’s Health*, 11, pp. 287–299. Available at: <https://doi.org/10.2147/IJWH.S197604>.
- Pankowska, K.A., Będkowska, G.E., Chociej-Stypułkowska, J., Rusak, M., Dąbrowska, M. and Osada, J. (2023) ‘Crosstalk of Immune Cells and Platelets in an Ovarian Cancer Microenvironment and Their Prognostic Significance’, *International Journal of Molecular Sciences*, 24(11). Available at: <https://doi.org/10.3390/ijms24119279>.

- Pavone, M.E. and Lyttle, B.M. (2015) 'Endometriosis and ovarian cancer: Links, risks, and challenges faced', *International Journal of Women's Health*, 7, pp. 663–672. Available at: <https://doi.org/10.2147/IJWH.S66824>.
- Prodromidou, A., Andreakos, P., Kazakos, C., Vlachos, D.E., Perrea, D. and Pergialiotis, V. (2017) 'The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer', *Inflammation Research*, 66(6), pp. 467–475. Available at: <https://doi.org/10.1007/s00011-017-1026-6>.
- Qing, X., Liu, L. and Mao, X. (2022) 'A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis', *Computational and Mathematical Methods in Medicine*, 2022. Available at: <https://doi.org/10.1155/2022/9339325>.
- Sánchez-Prieto, M., Sánchez-Borrego, R., Lubián-López, D.M. and Pérez-López, F.R. (2022) 'Etiopathogenesis of ovarian cancer. An inflamm-aging entity?', *Gynecologic Oncology Reports*, 42. Available at: <https://doi.org/10.1016/j.gore.2022.101018>.
- Savant, S.S., Sriramkumar, S. and O'hagan, H.M. (2018) 'The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer', *Cancers*, 10(8). Available at: <https://doi.org/10.3390/cancers10080251>.
- Schweer, D., McAtee, A., Neupane, K., Richards, C., Ueland, F. and Kolesar, J. (2022) 'Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy', *Cancers*, 14, pp. 1–18. Available at: <https://doi.org/10.3390/cancers14092220>.
- Shih, I.M., Wang, Y. and Wang, T.L. (2021) 'The Origin of Ovarian Cancer Species and Precancerous Landscape', *American Journal of Pathology*, 191(1), pp. 26–39. Available at: <https://doi.org/10.1016/j.ajpath.2020.09.006>.

Soibi-Harry, A.P., Amaeshi, L.C., Garba, S.R. and Anorlu, R.I. (2021) ‘The relationship between pre-operative lymphocyte to monocyte ratio and serum cancer antigen-125 among women with epithelial ovarian cancer in Lagos, Nigeria’, *Ecancer*, 15(1288), pp. 1–7. Available at: <https://doi.org/10.3332/ECANCER.2021.1288>.

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) ‘Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries’, *CANCER J CLIN*, 71(3), pp. 209–249. Available at: <https://doi.org/10.3322/caac.21660>.

Tavares, V., Marques, I.S., Melo, I.G. de, Assis, J., Pereira, D. and Medeiros, R. (2024) ‘Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements’, *International Journal of Molecular Sciences*, 25(184), pp. 1–28. Available at: <https://doi.org/10.3390/ijms25031845>.

Timmerman, D., Planchamp, F., Bourne, T., Landolfo, C., Du Bois, A., Chiva, L., Cibula, D., Concin, N., Fischerova, D., Froyman, W., Gallardo Madueño, G., Lemley, B., Loft, A., Mereu, L., Morice, P., Querleu, D., Testa, A.C., Vergote, I., Vandecaveye, V., Scambia, G. and Fotopoulou, C. (2021) ‘ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors’, *International Journal of Gynecological Cancer*, 31(7), pp. 961–982. Available at: <https://doi.org/10.1136/ijgc-2021-002565>.

Torre, L.A., Trabert, B., DeSantis, C.E., Miller, K.D., Samimi, G., Runowicz, C.D., Gaudet, M.M., Jemal, A. and Siegel, R.L. (2018) ‘Ovarian cancer statistics, 2018’, *CA Cancer J Clin.*, 68(4), pp. 284–296. Available at: <https://doi.org/10.3322/caac.21456>.

- Toufakis, V., Katuwal, S., Pukkala, E. and Tapanainen, J. (2021) 'Impact of parity on the incidence of ovarian cancer subtypes: a population-based case-control study', *Acta Oncol*, 60(7), pp. 850–855. Available at: <https://doi.org/10.1080/0284186X.2021.1919754>.
- Urzua, U., Chacon, C., Lizama, L., Sarmiento, S., Villalobos, P., Kroxato, B., Marcelain, K. and Gonzalez, M.J. (2017) 'Parity history determines a systemic inflammatory response to spread of ovarian cancer in naturally aged mice', *Aging and Disease*, 8(5), pp. 546–557. Available at: <https://doi.org/10.14336/AD.2017.0110>.
- Winter-Roach, B.A., Kitchener, H.C. and Lawrie, T.A. (2014) 'Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer', *Cochrane Database of Systematic Reviews* [Preprint]. Available at: <https://doi.org/10.1002/14651858.CD004706.pub4>.
- Xia, Y.Y. and Kotsopoulos, J. (2022) 'Beyond the pill: contraception and the prevention of hereditary ovarian cancer', *Hereditary Cancer in Clinical Practice*, 20(1), pp. 1–9. Available at: <https://doi.org/10.1186/s13053-022-00227-z>.
- Yan, M., Han, M., Yang, X., Shen, R., Wang, H., Zhang, L., Xia, S., Yang, P., Zhai, G. and Shao, Q. (2021) 'Dual inhibition of EGFR and IL-6-STAT3 signalling by miR-146b: a potential targeted therapy for epithelial ovarian cancer', *Journal of Enzyme Inhibition and Medicinal Chemistry*, 36(1), pp. 1905–1915. Available at: <https://doi.org/10.1080/14756366.2021.1963240>.
- Ye, L., Zhou, G., Zhou, L., Wang, D., Xiong, S., Liu, C. and Zhang, G. (2023) 'Diagnostic roles of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein, and cancer antigen 125 for ovarian cancer', *Journal of International Medical Research*, 51(12). Available at: <https://doi.org/10.1177/03000605231218557>.

Yu, L., Guo, Y., Chang, Z., Zhang, D., Zhang, S., Pei, H., Pang, J., Zhao, Z.J. and Chen, Y. (2021) ‘Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies’, *Frontiers in Oncology*, 11(October), pp. 1–18. Available at: <https://doi.org/10.3389/fonc.2021.764119>.

Zamwar, U.M. and Anjankar, A.P. (2022) ‘Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer’, *Cureus*, 14(10). Available at: <https://doi.org/10.7759/cureus.30561>.

Zayyan, M.S. (2020) ‘Risk Factors for Ovarian Cancer’, *Tumor Progression and Metastasis* [Preprint].

Zhang, J. and Yu, K.F. (1998) ‘What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes’, *JAMA*, 280(19), pp. 1690–1691. Available at: <https://doi.org/10.1001/jama.280.19.1690>.

Zhou, J., Wu, S.G., Wang, J., Sun, J.Y., He, Z.Y., Jin, X. and Zhang, W.W. (2018) ‘The effect of histological subtypes on outcomes of stage IV epithelial ovarian cancer’, *Frontiers in Oncology*, 8(577), pp. 1–8. Available at: <https://doi.org/10.3389/fonc.2018.00577>.